USA flag logo/image

An Official Website of the United States Government

Label-Free Protein Array for Alzheimer's Disease Detection and Monitoring

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93337
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AG034720
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ZOIRAY TECHNOLOGIES, INC.
ZOIRAY TECHNOLOGIES, INC. 60 W RUTLAND SQ, #5 BOSTON, MA 02118 3039
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Label-Free Protein Array for Alzheimer's Disease Detection and Monitoring
Agency: HHS
Contract: 1R43AG034720-01
Award Amount: $169,656.00
 

Abstract:

DESCRIPTION (provided by applicant): We propose the development of a single-chip, multiplexed, label-free platform for Alzheimer's disease diagnosis and monitoring of protein markers in the cerebral spinal fluid (CSF). The Spectral Reflectance Imaging Bio sensor is a label-free protein array technology that can monitor real-time binding label-free at more than 1000 locations simultaneously. A unique feature of our system is that we very accurately quantify the levels of each marker, thus providing far great er reliability and diagnostic information for a broad range of potential markers. Long-term we seek to deliver a comprehensive platform that can rapidly, reliably, and inexpensively measure a broad spectrum of CSF biomarkers to identify the presence of neu rological disease and to assess its cause, extent, and progression. Ultimately the technology may be applied toward treatment monitoring and tailoring individual treatment plans. The immediate goal of this proposal is to provide proof-of-principle for the technology and to illustrate its successful utility in both the detection of CSF biomarkers and the quantitative measurement of markers specific for Alzheimer's disease. PUBLIC HEALTH RELEVANCE: The goal of the present work is to provide an advance d cerebral spinal fluid based detection and monitoring technique for Alzheimer's Disease. The technique aims to detect the presence and level of a large number of protein biomarkers that can be found in the cerebral spinal fluid which show great promise fo r detecting the onset and monitoring the progression of Alzheimer's Disease. Monitoring disease progression is critically important for understanding the disease, making accurate prognoses, and for tailoring treatment.

Principal Investigator:

David A. Bergstein

Business Contact:

David A. Bergstein
info@zoiray.com
Small Business Information at Submission:

ZOIRAY TECHNOLOGIES, INC.
ZOIRAY TECHNOLOGIES, INC. 60 W RUTLAND SQ, #5 BOSTON, MA 02118

EIN/Tax ID: 126196422
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No